IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Vivian I. TEICHBERG

Serial No.:

10/522,415

Filed:

January 26, 2005

For:

METHOD AND COMPOSITION FOR PROTECTING

NEURONAL TISSUE FROM DAMAGE INDUCED

BY ELEVATED GLUTAMATE LEVELS

Examiner: unknown

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1615

Attorney

Docket: 29147

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

Dated: December 22, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					Complete if Known			
			-		Application Number	10/522,415		
INFORMATION DISCLOSURE					Filing Date	July 31, 2003		
	SIA	TEMENT BY APP	LICAN	VT.	First Named Inventor	Vivian I. TEICHBERG		
(use as many sheets as necessary)					Art Unit	1615		
					Examiner Name	unknown		
Sheet		1	of	3	Attorney Docket Number	29147		
			U.S.	PATENT	DOCUMENTS			
Examiner Initials*	Cite No. 1	Document Number	Publication Date Name of Patentee or Applicant of Cited Document			Pages, Columns, Lines, Where Relevant Passages or Relevant		
		Number-Kind Code ^{2 (if known)}			Figures Appear			
	-			<u> </u>				
	-							
				_				
	_	-						
	L							

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6	
	1	PCT WO 99/21565	06-6-1999	Blass et al.			
	-					\dashv	
 _				-		\vdash	
						\Box	
	<u> </u>		<u></u>				
Examiner Signature				Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		n Act of 1995, no persons are required to respond to a collection of information un	Complete	
	Su	bstitute for form 1449A/PTO	Application Number	10/522,415
	INE	ORMATION DISCLOSURE	Filing Date	July 31, 2003
			First Named Inventor	Vivian I.
STATEMENT BY APPLICANT				TEICHBERG
		(use as many sheets as necessary)	Group Art Unit	1615
			Examiner Name	unkown
Sheet	2	Of 3	Attorney Docket Number	29147
		OTHER PRIOR ART – NON PATENT LITER	ATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the a item (book, magazine, journal, serial symposium, catalog, etc.) da publisher, city and/or country where properties of the author country where properties of the author catalog and the author (in CAPITAL LETTERS), title of the author catalog and the author c	te, page(s), volume-issue numb	of the per(s), T^2
	2	Matthews et al. "Enzymatic Degradation Protects Neur Excitotoxicity", Journal of Neurochemistry, 75(3): 104	ons From Glutamate	
	3	Jiang et al. "Glutamate Is A Principal Mediator of HIV		
	-	Competent Human Macrophage Neurotoxicity", Societ		racts
		26(1-2), Abstract No. 136.17, 30th Annual Meeting of		
		New Orleans, USA, 2000.	the Society of Neuroscie	ince,
	4	Di Giorgio et al. "Gabaergic Systems in Brain Regions	of Glutamata Lasianad	Dota!!
	7	Italien Journal of Biochemistry, 34(1): 19-28, 1985. P.		Rais,
	5	Engelhardt et al. "The Diagnostic Value of Enzyme De		oinal
		Fluid", Medizinische Klinik, München, 71(17): 699-70		
	6	Andrae et al. "Pyruvate and Related α-Ketoacids Protection		Culture
		Against Hydrogen Peroxide-Induced Cytotoxicity", To 1985.	xicology Letters, 28: 93-	-98,
	7		Carlanialia Cali Assassa	
	1'	Avramis et al. "A Randomized Comparison of Native I		
		and Polyethelyne Glycol Conjugated Asparaginase for	I realment of Children v	vitn
		Newly Diagnosed Standard-Risk Acute Lymphoblastic	E Leukemia: A Children's	}
	-	Cancer Group Study", Blood, 99(6): 1986-1994, 2002.		
	8	Cavallini et al. "The Protective Action of Pyruvate on I		
		Heart: Comparison With Other Oxidizable Substrates",	, Journal of Molecular Ce	ell
<u></u> _		Cardiology, 22: 143-154, 1990.		
	9	Desagher et al. "Pyruvate Protects Neurons Against Hy	drogen Peroxide-Induce	d
	10	Toxicity", The Journal of Neuroscience, 17(23): 9060-	9067, 1997.	
	10	Gramsbergen et al. "Pyruvate Protects Against 3-Nitro in Corticostriatal Slice Cultures", Neuropharmacology,	11(21): 2743-2747, 200	0.
	11	Hosoya et al. "Blood-Brain Barrier Produces Significan	nt Efflux of L-Aspartic A	cid
		But Not D-Aspartic Acid: In Vivo Evidence Using the	Brain Efflux Index Meth	iod",
		Journal of Neurochemistry, 73: 1206-1211, 1999.		
	12	Lee et al. "Protection by Pyruvate Against Transient Fo	orebrain Ischemia in Rats	5",
		The Journal of Neuroscience, 21(RC171): 1-6, 2001.		
	13	Liu et al. "P-Glycoprotein Regulated Transport of Glut	amate at Blood-Brain Ba	arrier",
		Acta Pharmacol Sin, 22(2): 111-116, 2001.		
	14	Matsumoto et al. "Role of Pyruvate in Ischemia-Like C	Conditions on Cultured	
		Neurons", Neurological Research, 16: 460-464, 1994.		
	15	Matthews et al. "Glutamate-Pyruvate Transaminase Pro		•
		Toxicity in Hippocampal Slices", Brain Research, 978:	59-64, 2003.	
	16	Matthews et al. "Enzymatic Degradation Protects Neur	ons From Glutamate	
		Excitotoxicity", Journal of Neurochemistry, 75: 1045-1		
	17	Maus et al. "Pyruvate and Lactate Protect Striatal Neur	ons Against N-Methyl-D)-
		Aspartate-Induced Neurotoxicity", European Journal of	f Neuroscience, 11: 3215	5-
		3224, 1999.		
	18	Mongan et al. "Pyruvate Improves Cerebral Metabolism		
	1	Shock", AJP - Heart and Circulatory Physiology, 281:		
	19	Mongan et al. "Intravenous Pyruvate Prolongs Surviva		
		in Swine", AJP - Heart and Circulatory Physiology, 27	7(46): H2253-H2263, 19	999.
	20	O'Kane et al. "Na+-Independent Glutamate Transporter	rs (EAAT1, EAAT2, and	i
		EAAT3) of the Blood-Brain Barrier", The Journal of B	iological Chemistry, 274	l(45):
		31891-31895, 1999.		

0 40			
DEC 2 8 2005 H	21	Ruiz et al. "Protection by Pyruvate and Malate Against Glutamate-Mediated Neurotoxicity", NeuroReport, 9: 1277-1282, 1998.	_
	22	Ryu et al. "Neuroprotective Effects of Pyruvate in the Quinolinic Acid Rat Model of Huntington's Disease", Experimental Neurology, 183: 700-704, 2003.	
TRADEMA	23	Steele "Blood-Brain Barrier Transport of the α-Keto Acid Analogs of Amino Acids", Federation Proceedings, 45(7): 2060-2064, 1986	
	24	Stover et al. "Neurotransmitters in Cerebrospinal Fluid Reflect Pathological Activity", European Journal of Clinical Investigation, 27: 1038-1043, 1997.	
	25	Wolff et al. "The Effectiveness of Benzoate in the Management of Seizures in Nonketotic Hyperglycinemia", AJDC, 140: 596-602, 1986.	

Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.